Collaboration Streamlines Data Analysis Workflow, Offers Powerful Solution for Multi-Parameter Data Analysis

FREMONT, Calif., January 8, 2019 – Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, today announced that its Aurora and Northern Lights series of flow cytometry systems will now include FCS Express™, a powerful flow cytometry data analysis solution from De Novo Software.

FCS Express, De Novo Software's flagship product, turns flow cytometry data analysis into results. FCS Express rapidly analyzes flow cytometry data using industry-leading flow cytometry tools, plots and gates, which are exported directly to Microsoft Office™ products including PowerPoint™, Excel™ and Word™. Used by many leading clinical and research laboratories, FCS Express provides comprehensive analysis capabilities, including advanced and easy-to-use report creation tools, 21 CFR Part 11 data security support, quality control alerts, real time bar and scatter plots with updating regression analysis, and much more.

“De Novo’s software is an ideal complement to our flow cytometry solutions,” noted Dr. Wenbin Jiang, CEO of Cytek Biosciences. “The advanced analysis and reporting capabilities enabled by FCS Express will allow scientists to fully exploit the unique spectral capabilities of our systems. The spectral technology behind Aurora and Northern Lights enables scientists to obtain deeper biological insights from a single sample, and FCS Express streamlines their workflows when using our systems – so that they can get to their answers faster.”

David Novo, president of De Novo Software, commented: "We are thrilled to be working with Cytek. Spectral flow cytometry is one of the most important innovations in the field in the last 20 years. Aurora’s rapid acceptance in the marketplace is a testament to Cytek’s remarkable engineering and technology innovation. Developing analytical tools for this cutting-edge technology will help drive our own innovations – and keep us at the forefront of the market.”

In collaboration with Cytek, De Novo Software has added the capability to seamlessly read the raw spectral data along with the unmixed FCS file. Users can then display, gate, color code, and compare the raw spectral data itself using specialized spectral plots in FCS Express designed specifically for spectral data analysis. De Novo Software has plans to dramatically expand the range of analysis tools for spectral data in the upcoming year.

Cytek’s intuitive, advanced flow cytometers bring deep biological insights and capabilities that go beyond flow cytometry systems with a much higher price tag. Cytek’s Aurora and Northern Lights series of flow cytometry systems with a one-year license of FCS Express are now available. Systems purchased after July 6, 2018 are eligible to receive a license as well.

Please visit www.cytekbio.com for more information.

About De Novo Software

De Novo Software is a leading provider of flow and image cytometry analysis. Its primary product, FCS Express, is used by over 3,000 laboratories worldwide for research purposes, and dozens of clinical laboratories for high-throughput clinical analysis. As the first third-party flow analysis software listed with the FDA for in-vitro diagnostic use, and with full 21 CFR Part 11 compliance features, FCS Express is the analysis tool of choice for the clinical laboratory. In addition, De Novo Software has extensive experience creating custom data analysis solutions and integrating with large scale LIS and HIS systems. For more information, please visit www.denovosoftware.com.

About Cytek Biosciences, Inc.

Cytek Biosciences Inc. is a leading flow cytometry solution provider that develops compact, affordable instruments with high multiplexing capability and a wide range of services to support scientists and clinicians. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. To learn more, follow Cytek on LinkedIn, Twitter and Facebook.